跳至主要内容
临床试验/NCT03532763
NCT03532763Unknown不适用

Anti-Inflammatory Effect of Tocotrienol Supplementation in Subjects With Moderately Elevated Inflammation

Malaysia Palm Oil Board2 个研究点 分布在 1 个国家目标入组 180 人开始时间: 2018年4月19日最近更新:
适应症
干预措施

试验速览

阶段
不适用
入组人数
180
试验地点
2
主要终点
Inflammation

研究概览

简要总结

The objective of this study is to address the anti-inflammatory effect of tocotrienol supplementation in subjects with moderately elevated inflammation.

It is hypothesized that 6 months supplementation of tocotrienols will reduce inflammatory markers of subjects.

详细描述

A double-blind, randomized, placebo-controlled, parallel study comparing the effect of tocotrienols vs. placebo will be conducted in subjects with moderately elevated inflammation. Subjects will be supplemented with Tocovid Suprabio 200 mg twice daily or placebo for 6 months. Fasting blood samples will be collected at baseline, 3 months, 6 months. A post-study fasting blood sample will be collected at 9 months.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Prevention
盲法
Double (Participant, Investigator)

入排标准

年龄范围
30 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • Age 30-60
  • Elevated plasma hs-CRP level of > 1 mg/L < 10 mg/L

排除标准

  • Subjects with very high LDL-cholesterol ≥ 4.9 mmol/L
  • Subjects with very high hs-CRP level ≥ 10 mg/L
  • Pregnancy or lactation
  • Current use of vitamin E or corticosteroids
  • Significant hepatic and renal impairment
  • Fever, cold or infection during bleeding day

研究组 & 干预措施

Tocotrienol-rich fraction

Experimental

干预措施: Tocotrienol-rich fraction (Dietary Supplement)

Placebo

Placebo Comparator

干预措施: Placebo (Dietary Supplement)

结局指标

主要结局

Inflammation

时间窗: 0, 3, 6, 9 months

Change in high-sensitivity c-reactive protein (hs-CRP)

次要结局

  • Inflammatory markers(0, 3, 6, 9 months)
  • Thrombotic markers(0, 3, 6, 9 months)
  • Lipid profile(0, 3, 6, 9 months)
  • Glucose homeostasis(0, 3, 6, 9 months)

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验